Current update claims 69 of 84 either recruiting or active, no longer recruiting.
15 site locales are listed as not yet recruiting. Seems slow to me...
Makes me wonder if there's a connection between the slow recruitment and the short play enabling the convertible tango. It might help account for a run of closings below the $6.90 target.
Wash Rinse. Repeat. The cycle does persist, does it not?
I'm not sure why Comet 2 is enrolling so slowly as compared to Comet 1. My guess is that Mito (control arm) is just not used very much any more and with 1:1 randomization, onc's would rather put their patients in other trials than have them get a 50/50 shot at Mito or Cabo. Perhaps it's the inconvenience of the infusion visits, I had expected Comet 2 to finish enrolment some time ago.
I had considered the possibility that Mito use had been diminished by adoption of Zoledronic acid and Denosumab. I recall a Doc Matt Smith quote back in 2010 (at Xgeva approval), claiming that 3 out of 4 mPC patients were going untreated for bone health. Since then, of course, there's been a big push on urologists to address bone issues. I haven't seen recent stats, but in addition to the rash of recent treatment approvals in mCRPC, maybe bone health issues are getting the treatment they deserve. Mito's a kind of a dinosaur anyway, isn't it?